Skip to content

The Association of Transgelin-2, Metallothionein-2 and Ezrin With Asthma

The Association of Transgelin-2, Metallothionein-2 and Ezrin With Asthma: A Case-control Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05496582
Enrollment
100
Registered
2022-08-11
Start date
2022-11-01
Completion date
2026-12-31
Last updated
2024-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Brief summary

Asthma is one of the most common chronic respiratory diseases. Previous study found a series of differentially expressed genes and proteins (transgelin-2, metallothionein-2, ezrin) in asthmatic rat. The aim of the study is to investigate the changes and associations of these gene with asthma in human.

Detailed description

This study will investigate the changes and associations in asthma. In this project, the investigators will explore the changes of gene expression of transgelin-2, metallothionein-2 and ezrin in asthma and investigate their correlation with current diagnosis markers of asthma, including pulmonary function, fractional exhaled nitric oxide,eosinophil counts,immunoglobulin E, interleukin-5, etc.

Interventions

DIAGNOSTIC_TESTNo intervention

No intervention

Sponsors

Xiangya Hospital of Central South University
CollaboratorOTHER
National Natural Science Foundation of China
CollaboratorOTHER_GOV
Shanghai University of Traditional Chinese Medicine
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
14 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

1. Males or females, aged 14-75 years; 2. Patients with a definite diagnosis of bronchial asthma; 3. The diagnosis of asthma according to the Global Initiative for Asthma (GINA), with positive bronchodilator responsiveness (reversibility) test; 4. Healthy volunteers without respiratory symptoms such as cough, wheezing, chest tightness or dyspnea; 5. Agree with all procedures in this trial by signing a written informed consent form.

Exclusion criteria

1. Patients with chronic obstructive pulmonary disease or other airway disease; 2. Complicated with other severe primary diseases (including hypertension, cancer, hyperthyroidism, bronchiectasia, cardiac insufficiency) and conditions that would prevent participation in the trial or put the participant at risk; 3. Women who are known to be pregnant or breastfeeding; 4. Not willing to participate; 5. Psychiatric history and neurological disorders can not work normally; 6. Other conditions that the researcher considers inappropriate to participate in this study.

Design outcomes

Primary

MeasureTime frameDescription
Difference in gene expression of transgelin-2, metallothionein-2 and ezrin between controls and asthmatic patientsTwo yearPCR test of gene expression of transgelin-2, metallothionein-2 and ezrin between controls and asthmatic patients
Association of transgelin-2, metallothionein-2 and ezrin with asthmaTwo yearCorrelation analysis between gene expressions of transgelin-2, metallothionein-2, ezrin and current asthmatic tests (pulmonary function, fractional exhaled nitric oxide,immunoglobulin E, serum eosinophil counts, interleukin-5, etc)

Countries

China

Contacts

Primary ContactLei-Miao Yin, MD
collegeylm@shutcm.edu.cn13774384237
Backup ContactJun-Tao Feng, MD
jtfeng1976@csu.edu.cn13786145799

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026